Dive into a realm of knowledge curated from leading institutions and researchers globally, shaping the future of therapeutic solutions, where we unlock the mysteries of medical cannabis through studies and breakthrough insights.
Our commitment is to empower you with knowledge, bridging the gap between groundbreaking research and your understanding. Explore the potentials, benefits, and advancements in medical cannabis, making informed decisions for your well-being.
For over two decades, MedUni Vienna has researched the human endocannabinoid system and the effects of cannabis. Despite therapeutic successes, Austria lacks secure cannabinoid medications. Neurobiologist Tibor Harkany emphasizes in the journal „Science“ the potential of medical cannabis and calls for evidence-based studies.
Despite sociopolitical hurdles, he sees a clear need for specific, standardized applications of cannabis in clinical trials. Psychiatrist Siegfried Kasper shares this conviction, advocating for more research to integrate cannabis into scientific medicine with a solid foundation.
Cannabinoids, primarily THC and CBD, activate CB1 and CB2 receptors, exhibiting therapeutic effects. Over 100 controlled clinical studies support cannabis-based medications. Studies confirm efficacy in neuropathic pain, chemotherapy-induced nausea, HIV/AIDS-related anorexia, and chronic pain. Cannabinoids also show promise in MS-related bladder dysfunction, Tourette’s tics, and levodopa-induced dyskinesias in Parkinson’s.
Despite positive findings, further research is essential for a comprehensive evaluation of cannabinoids‘ potential benefits across various conditions.
A 6-week medical cannabis therapy demonstrated potential benefits for individuals with chronic depression. In a pilot study, nearly a quarter of participants experienced a halving of depression severity. Led by Dr. Norbert Scherbaum, the study highlights early indications of medical cannabis efficacy and safety in depression treatment. Future research aims to validate these findings through prospective controlled studies. Notably, Algea Care facilitated the pilot study, using telemedicine for participant registration and evaluation by specialized physicians. The retrospective study involved 59 individuals with previously unsuccessful medication-based depression treatment.
Over 18 weeks, depression severity significantly decreased (p<0.001), with a 22% dropout rate. Approximately 50% showed positive treatment response, and concurrent antidepressant use did not impact results. Adverse effects, mostly mild, were observed in 35.6% of participants, emphasizing the potential of medical cannabis in cases where traditional approaches fall short.
Sie sehen gerade einen Platzhalterinhalt von Google Maps. Um auf den eigentlichen Inhalt zuzugreifen, klicken Sie auf die Schaltfläche unten. Bitte beachten Sie, dass dabei Daten an Drittanbieter weitergegeben werden.
Mehr Informationen